Stock listing

Dusseldorf:12V Veracyte, Inc. Aktie

German listing (Dusseldorf) of Veracyte, Inc. · home listing NASDAQ:VCYT

Follow Veracyte, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:VCYT

$25.13 USD -0.44 (-1.7%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:VCYT

Past year -38.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$24.53 – $25.60 USDNov 20, 2026
Volume
2.79M sharesNov 20, 2026
Market cap
$2.03B USDAt the close on Nov 20, 2026 · price × 80.70M shares outstanding
52-week range
$21.91 – $60.91 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$67.66M USDMedian day 1.37M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Veracyte, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VCYT · Home$25.13 USD-0.44 (-1.7%)2,792,810$24.63$25.60$24.53$25.57Close on Nov 20, 2026
Frankfurt:12V€22.29 EUR-1.12 (-4.8%)—€22.29€22.29€22.29€23.41Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VCYT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$25.13-0.44-1.7%$24.63$25.60$24.532,792,810
$25.57+1.34+5.5%$24.23$25.65$24.172,445,776
$24.23+0.22+0.9%$23.99$24.47$23.602,920,810
$24.01-0.32-1.3%$23.97$24.57$23.272,188,981
$24.33-0.30-1.2%$24.60$24.65$23.472,029,307
$24.63-0.48-1.9%$24.60$25.29$24.072,507,764
$25.11+1.05+4.4%$25.20$25.84$24.803,339,730
$24.06-1.86-7.2%$25.52$25.88$23.734,463,164
$25.92+1.76+7.3%$24.40$26.25$23.805,062,907
$24.16+0.16+0.7%$23.84$24.99$22.506,579,942
$24.00-28.52-54.3%$29.59$29.79$21.9114,972,472
$52.52+2.23+4.4%$52.35$52.76$49.291,834,513
$50.29+1.29+2.6%$49.95$51.42$49.881,082,104
$49.00-1.01-2.0%$50.43$50.61$48.901,150,177
$50.01-2.16-4.1%$51.54$51.93$49.651,015,333
$52.17+1.86+3.7%$50.82$52.39$49.631,231,141
$50.31+0.03+0.1%$50.00$51.79$49.871,397,992
$50.28+2.08+4.3%$48.06$52.25$47.331,809,888
$48.20+0.27+0.6%$48.24$48.96$47.70748,098
$47.93+1.89+4.1%$45.87$48.07$45.48906,000
$46.04-0.18-0.4%$45.98$46.63$45.291,203,500
$46.22+1.43+3.2%$44.17$46.43$43.90812,300
$44.79+0.99+2.3%$43.91$45.17$43.471,136,400
$43.80+0.68+1.6%$43.70$45.01$43.45725,400
$43.12-1.27-2.9%$45.00$45.75$42.832,063,200
$44.39+0.88+2.0%$43.36$45.58$42.701,227,200
$43.51+0.40+0.9%$42.37$43.99$42.20935,300
$43.11-0.91-2.1%$43.67$44.29$43.04760,400
$44.02-1.21-2.7%$45.18$45.22$43.291,151,600
$45.23+1.63+3.7%$43.71$46.17$43.50966,500
$43.60+0.44+1.0%$42.50$43.67$41.221,221,600
$43.16-1.49-3.3%$44.04$44.21$42.341,213,600
$44.65-3.02-6.3%$48.00$48.84$44.091,730,800
$47.67+1.86+4.1%$45.75$47.79$45.001,289,100
$45.81+1.62+3.7%$44.94$46.09$44.411,041,700
$44.19-1.85-4.0%$45.66$47.14$44.181,426,700
$46.04-0.04-0.1%$45.93$46.78$45.601,184,200
$46.08+0.85+1.9%$46.00$47.52$45.211,594,800
$45.23-0.20-0.4%$45.04$47.52$44.471,696,500
$45.43-3.11-6.4%$49.00$49.00$45.361,725,700
$48.54+4.72+10.8%$43.66$48.95$43.512,880,200
$43.82+0.46+1.1%$42.95$43.86$42.251,525,500
$43.36+1.84+4.4%$41.76$43.74$41.321,472,500
$41.52+1.725+4.3%$40.00$41.98$39.401,470,500
$39.80-0.775-1.9%$40.41$41.05$39.552,667,600
$40.57+2.07+5.4%$39.67$40.70$38.801,470,300
$38.50-1.64-4.1%$40.36$41.45$38.251,622,100
$40.14-1.07-2.6%$40.83$42.36$39.101,760,600
$41.21+0.34+0.8%$41.17$41.40$40.501,032,500
$40.87-1.16-2.8%$42.61$42.66$40.791,001,600
$42.03-1.83-4.2%$43.18$43.78$41.64849,400
$43.86+1.41+3.3%$42.79$44.20$42.391,450,100
$42.45-0.08-0.2%$41.81$43.28$41.57962,000
$42.53-2.14-4.8%$44.21$44.81$42.43992,000
$44.67-0.21-0.5%$45.36$45.99$44.12673,700
$44.88+1.45+3.3%$43.51$45.65$43.481,371,700
$43.43+0.24+0.6%$42.97$43.74$42.28873,000
$43.19-0.15-0.3%$42.33$43.34$41.601,472,100
$43.34-1.91-4.2%$45.21$45.55$43.321,684,100
$45.25+0.96+2.2%$44.20$45.50$44.191,328,200
$44.29+0.25+0.6%$43.78$44.52$43.252,181,500
$44.04+2.57+6.2%$42.01$44.10$41.811,155,347
$41.47-0.84-2.0%$42.00$42.07$41.021,165,433
$42.31+0.52+1.2%$42.18$42.54$41.101,005,500
$41.79-0.40-0.9%$41.67$42.45$41.05980,400
Ticker
Dusseldorf:12V
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Veracyte, Inc. news

Veracyte, Inc. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
27 in the last 12 months · 261 in all · newest Nov 4, 2026 · oldest 2019
Calls
25 calls with a replay · 25 with a transcript · latest Nov 4, 2026
Decks
19 decks · latest Jul 30, 2026

Where Veracyte, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VCYT · Home listingNASDAQUnited StatesUSD
gettex:12VgettexGermanyEUR
BOATS:VCYTBOATSUnited StatesUSD
LS Exchange:A1W7EALS ExchangeGermanyEUR
Lang & Schwarz:A1W7EALang & SchwarzGermanyEUR
Tradegate:12VTradegateGermanyEUR
Dusseldorf:12V · This pageDusseldorfGermanyEUR
Frankfurt:12VFrankfurtGermanyEUR
Munich:12VMunichGermanyEUR
Hamburg:12VHamburgGermanyEUR
Stuttgart:12VStuttgartGermanyEUR

Valuation

P/E 16.0× against a median of 58.0×: the lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.70B USD
P/E
16.0×
EV/sales
2.9×
EV/EBITDA
14.0×
Price/book
1.4×
Gross margin
72.0%
Operating margin
17.1%
Net margin
21.8%
Debt to equity
0.0×
Beta vs S&P 500
1.34

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Veracyte, Inc. · NASDAQ:VCYTUS$2.03BUS$1.70B16.0×2.9×14.0×1.4×21.8%0.0×1.34
Oxford Nanopore Technologies PLC · LSE:ONTUS$2.42BUS$2.23Bn/a7.6×n/a4.4×−64.8%0.1×n/a
OneSource Specialty Pharma Limited · NSE:ONESOURCEUS$1.99BUS$2.18Bn/a12.0×50.9×3.1×−0.1%0.3×n/a
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A · SSE:603456US$1.97BUS$1.77B22.0×2.2×n/a1.5×11.3%0.0×n/a
Azenta, Inc. · NASDAQ:AZTAUS$1.96BUS$1.63Bn/a2.6×n/a1.4×−26.9%0.0×1.59
Syngene International Ltd. · NSE:SYNGENEUS$1.96BUS$1.96B97.5×5.2×20.0×3.7×5.3%0.1×n/a
Cohance Lifesciences Ltd · NSE:COHANCEUS$1.91BUS$1.88B167×8.1×55.1×4.5×5.0%0.1×n/a
Alamar Biosciences, Inc. · NASDAQ:ALMRUS$1.84BUS$1.66Bn/a14.5×n/a6.1×−48.2%0.1×1.70
Fortrea Holdings Inc. · NASDAQ:FTREUS$1.79BUS$2.62Bn/a1.0×28.7×3.4×−2.6%2.0×1.68
ChemoMetec A/S · OMXCOP:CHEMMUS$1.72BUS$1.68B58.0×22.3×40.6×16.1×39.5%0.0×n/a
GemPharmatech Co., Ltd. Class A · SSE:688046US$1.65BUS$1.49B54.4×10.5×n/a4.7×21.5%0.0×n/a
Median of the othersUS$1.93BUS$1.83B58.0×7.9×40.6×4.0×2.4%0.1×1.68

Forecasts

7 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
41.60 USD · Analysts' mean
EPS, year to Dec 2026
1.94 · 10 analysts
Revenue, year to Dec 2026
590.8M · 11 analysts

Team and board

Officers

OfficerRole
Marc StapleyChief Executive Officer
Kevin HaasChief Development and Technology Officer

Board

DirectorRole
Robert S. EpsteinChairman
Brent ShaferBoard Member
Eliav BarrBoard Member
Evan JonesBoard Member
Jens HolsteinBoard Member
Karin EasthamBoard Member
Muna BhanjiBoard Member
Tom Miller

Events

Calls

CallWhenStatus
Veracyte (NASDAQ:VCYT) Q3 2026 Earnings CallWed, Nov 04, 2026 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q2 2026 Earnings CallThu, Jul 30, 2026 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q1 2026 Earnings CallTue, May 05, 2026 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q4 2025 Earnings CallWed, Feb 25, 2026 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q3 2025 Earnings CallTue, Nov 04, 2025 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q2 2025 Earnings CallWed, Aug 06, 2025 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q1 2025 Earnings CallWed, May 07, 2025 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q4 2024 Earnings CallMon, Feb 24, 2025 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q3 2024 Earnings CallWed, Nov 06, 2024 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q2 2024 Earnings CallTue, Aug 06, 2024 · 4:30 PM ETReplay
All 25 calls
CallWhenStatus
Veracyte (NASDAQ:VCYT) Q1 2024 Earnings CallTue, May 07, 2024 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q4 2023 Earnings CallThu, Feb 22, 2024 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q3 2023 Earnings CallTue, Nov 07, 2023 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q2 2023 Earnings CallTue, Aug 08, 2023 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q1 2023 Earnings CallThu, May 04, 2023 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q4 2022 Earnings CallWed, Feb 22, 2023 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q3 2022 Earnings CallWed, Nov 02, 2022 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q2 2022 Earnings CallTue, Aug 02, 2022 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q1 2022 Earnings CallTue, May 03, 2022 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q4 2021 Earnings CallMon, Feb 28, 2022 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q3 2021 Earnings CallTue, Nov 09, 2021 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q2 2021 Earnings CallThu, Jul 29, 2021 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q1 2021 Earnings CallMon, May 10, 2021 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q4 2020 Earnings CallWed, Feb 17, 2021 · 4:30 PM ETReplay
Veracyte (NASDAQ:VCYT) Q3 2020 Earnings CallMon, Nov 02, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−54.3%
Q2 2026Jul 30, 2026 · After close−22.5%
Q1 2026May 5, 2026 · After close+24.9%
Q4 2025Feb 25, 2026+8.6%
Q3 2025Nov 4, 2025 · After close+27.5%
Q2 2025Aug 6, 2025 · After close+15.5%
Q1 2025May 7, 2025 · After close+1.2%
Q4 2024Feb 20, 2025 · Before open−2.5%
Q3 2024Nov 6, 2024 · After close+2.0%
Q2 2024Aug 6, 2024 · After close+24.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close−4.3%
Q4 2023Feb 22, 2024 · After close−8.9%
Q3 2023Nov 7, 2023 · After close−3.6%
Q2 2023Aug 8, 2023 · After close+7.0%
Q1 2023May 4, 2023 · After close+4.6%
Q4 2022Feb 22, 2023 · After close+0.1%
Q3 2022Nov 2, 2022 · After close+24.3%
Q2 2022Aug 2, 2022 · After close−6.0%
Q1 2022May 3, 2022 · After close+4.6%
Q4 2021Feb 28, 2022 · After close+0.9%

Open Events

Decks

DeckKindSlidesDate
Q2 2026 Earnings PresentationEarnings23 slidesJul 30, 2026
Investor Presentation (June 2026)Investor deck20 slidesJun 1, 2026
Q1 2026 Earnings PresentationEarnings22 slidesMay 5, 2026
Raymond James Institutional Investor Conference 2026Conference33 slidesMarch 2026
Q4 2025 Earnings PresentationEarnings27 slidesFeb 25, 2026
Q3 2025 Earnings PresentationEarnings22 slidesNov 4, 2025
Q1 2025 Earnings PresentationEarnings24 slidesMay 7, 2025
Q4 2024 Earnings PresentationEarnings26 slidesFeb 24, 2025
Q2 2024 Earnings PresentationEarnings15 slidesAug 6, 2024
Q1 2024 Earnings PresentationEarnings16 slidesMay 7, 2024
All 19 decks
DeckKindSlidesDate
Q4 2023 Earnings PresentationEarnings16 slidesFeb 22, 2024
Q3 2023 Earnings PresentationEarnings17 slidesNov 7, 2023
Q2 2023 Earnings PresentationEarnings17 slidesAug 8, 2023
Q1 2023 Earnings PresentationEarnings17 slidesMay 4, 2023
Q1 2022 Earnings PresentationEarnings15 slidesMay 3, 2022
Merger or Acquisition (February 2021)Merger or acquisition18 slidesFeb 3, 2021
Merger or Acquisition (February 2021)Merger or acquisition17 slidesFeb 3, 2021
Technical Presentation (2020)Technical7 slides2020
Investor Presentation (October 2019)Investor deck17 slidesOct 22, 2019

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue517.1M445.8M361.1M296.5M219.5M117.5M120.4M92.0M72.0M65.1M
Cost of revenue157.1M147.6M112.9M101.6M74.4M41.5M36.1M33.1M28.2M25.5M
Gross profit362.5M298.1M229.7M175.7M145.1M76.0M83.8M58.9M43.8M39.6M
Research and development70.8M69.3M57.3M40.6M29.8M17.2M14.9M14.8M13.9M15.3M
Selling, general and administrative110.8M178.3M157.6M76.5M101.4M36.7M29.0M24.0M23.1M23.8M
Operating income57.8M16.1M-85.8M-41.1M-81.9M-35.4M-15.1M-22.2M-26.5M-28.8M
Depreciation and amortization21.4M23.5M27.2M25.9M19.6M7.94M4.12M3.92M3.84M3.51M
EBITDA79.2M39.6M-58.6M-15.2M-62.3M-27.4M-11.0M-18.3M-22.7M-25.3M
Interest expense1.00K2.00K15.0K198.0K241.0K229.0K677.0K1.96M4.94M2.76M
Income before tax68.2M25.7M-76.6M-36.4M-81.6M-34.9M-12.6M-23.0M-31.0M-31.4M
Income tax1.85M1.61M-2.21M133.0K-6.09M00000
Net income66.4M24.1M-74.4M-36.6M-75.6M-34.9M-12.6M-23.0M-31.0M-31.4M
Earnings per share, basic0.840.32-1.02-0.51-1.11-0.66-0.27-0.62-0.91-1.09
Earnings per share, diluted0.820.31-1.02-0.51-1.11-0.66-0.27-0.62-0.91-1.09

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents362.6M239.1M216.5M154.2M173.2M349.4M159.3M78.0M33.9M59.2M
Short-term investments50.3M50.4M024.6M3.96M0120.0K
Receivables44.7M46.5M40.4M44.0M41.5M18.5M19.3M13.2M12.7M8.76M
Inventory20.5M21.8M16.1M14.3M11.2M4.66M6.81M3.40M5.32M3.48M
Current assets488.4M372.3M285.6M248.6M243.1M375.7M187.7M97.0M53.9M73.6M
Property, plant and equipment17.7M15.1M8.99M8.93M8.94M9.69M11.5M
Goodwill767.2M745.8M703.0M695.9M707.9M2.73M2.73M1.06M1.06M1.06M
Total assets1.41B1.30B1.11B1.16B1.19B457.2M275.2M120.6M78.7M101.0M
Accounts payable4.59M8.63M12.9M11.9M12.4M3.12M2.33M2.52M3.85M2.42M
Current liabilities59.9M78.6M61.2M62.6M64.2M16.8M17.5M13.1M12.0M11.5M
Long-term debt0810.0K694.0K23.9M24.9M24.9M
Total debt39.7M50.7M12.6M01.13M810.0K694.0K25.3M24.9M24.9M
Total liabilities96.4M124.1M70.8M81.2M91.3M35.9M35.8M40.9M41.4M41.5M
Shareholders' equity1.31B1.18B1.04B1.08B1.10B421.2M239.5M79.8M37.2M59.6M
Shares outstanding79.4M77.8M73.3M72.0M71.1M58.2M49.6M40.9M33.8M33.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations136.3M75.1M44.2M7.54M-31.6M-9.71M-3.23M-13.5M-23.9M-28.0M
Capital spending-9.68M-11.3M-9.96M-8.55M-5.38M-2.84M-2.76M-1.87M-1.75M-4.21M
Free cash flow126.6M63.8M34.3M-1.01M-37.0M-12.5M-5.99M-15.4M-25.7M-32.2M
Cash from investing-9.21M-56.3M15.1M-29.4M-739.2M-3.84M-42.7M-1.87M-1.31M-4.21M
Cash from financing-4.22M4.90M2.84M3.49M596.3M203.6M127.3M59.5M-218.0K52.3M
Dividends paid-3.17M-3.85M-977.0K00
Share buybacks-6.74M-3.17M-9.03M-3.85M-977.0K-30.0K2.10M33.2M
Change in cash123.6M23.3M62.3M-18.9M-176.0M190.0M81.3M44.1M-25.4M20.1M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipOct 29, 2026Insider tradeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
144 · Notice of proposed saleOct 27, 2026Other filingsSEC
144 · Notice of proposed saleOct 27, 2026Other filingsSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleSep 24, 2026Other filingsSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
144 · Notice of proposed saleSep 21, 2026Other filingsSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
8-K · Current reportSep 14, 2026Acquisition or disposalSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
10-Q · Quarterly reportJul 31, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Management or board changeSEC
S-8 · Registration statement for employee plansJun 10, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 5, 2026Big-stake noticeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
144 · Notice of proposed saleMay 20, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
144 · Notice of proposed saleMay 6, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 22, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2026Meeting noticeSEC
4 · Change in ownershipApr 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
3 · Initial statement of ownershipMar 25, 2026Insider tradeSEC
8-K · Current reportMar 16, 2026Management or board changeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 25, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 3, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2026Big-stake noticeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
144 · Notice of proposed saleNov 25, 2025Other filingsSEC
144 · Notice of proposed saleNov 25, 2025Other filingsSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2025Big-stake noticeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
144 · Notice of proposed saleNov 5, 2025Other filingsSEC
144 · Notice of proposed saleNov 5, 2025Other filingsSEC
144 · Notice of proposed saleNov 5, 2025Other filingsSEC
144 · Notice of proposed saleNov 5, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeNov 4, 2025Big-stake noticeSEC
8-K · Current reportNov 4, 2025ResultsSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
144 · Notice of proposed saleOct 6, 2025Other filingsSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
144 · Notice of proposed saleSep 19, 2025Other filingsSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
144 · Notice of proposed saleSep 4, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 1, 2025Big-stake noticeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
8-K · Current reportJun 18, 2025Management or board changeSEC
S-8 · Registration statement for employee plansJun 17, 2025Offer documentSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
144 · Notice of proposed saleJun 13, 2025Other filingsSEC
144 · Notice of proposed saleJun 13, 2025Other filingsSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 6, 2025Big-stake noticeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
144 · Notice of proposed saleJun 4, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 7, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 7, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Veracyte, Inc.’s releases · as of Oct 30, 2026

Common shares
80,695,480
Fully diluted
80,695,480

Fully diluted

LineSharesAs of
Common shares80,695,480Oct 30, 2026

Share count over time

CountShares
Oct 30, 202680,695,480

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
BlackRock13.9MUS$639MSep 30, 2026
Vanguard9.14MUS$421MSep 30, 2026
Fidelity6.51MUS$300MSep 30, 2026
State Street5.53MUS$255MSep 30, 2026
ARK2.96MUS$136MSep 30, 2026
William Blair Investment Management, LLC2.71MUS$125MSep 30, 2026
Dimensional2.69MUS$124MSep 30, 2026
GW&K Investment Management, LLC2.41MUS$111MSep 30, 2026
Artisan Partners Limited Partnership2.31MUS$106MSep 30, 2026
Goldman Sachs2.24MUS$103MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Geode Capital2.1MUS$96.8MSep 30, 2026
Wellington1.97MUS$90.6MSep 30, 2026
Congress Asset Management Co1.95MUS$90MSep 30, 2026
First Trust1.81MUS$83.5MSep 30, 2026
Fuller & Thaler Asset Management, Inc.1.62MUS$74.7MSep 30, 2026
Arrowstreet Capital, Limited Partnership1.58MUS$72.8MSep 30, 2026
Bank of America1.41MUS$65MSep 30, 2026
Morgan Stanley1.01MUS$46.6MSep 30, 2026
Schwab983KUS$45.3MSep 30, 2026
Legal & General973KUS$44.8MSep 30, 2026
Vaughan Nelson Investment Management, L.P.966KUS$44.5MSep 30, 2026
Northern Trust957KUS$44MSep 30, 2026
Driehaus Capital Management LLC802KUS$36.9MSep 30, 2026
Amova Asset Management Americas, Inc.784KUS$36.1MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.784KUS$36.1MSep 30, 2026
Fisher Asset Management, LLC683KUS$31.4MSep 30, 2026
Loomis Sayles & Co L P671KUS$30.9MSep 30, 2026
Boston Partners661KUS$30.4MSep 30, 2026
Bamco Inc651KUS$30MSep 30, 2026
Artemis Investment Management LLP643KUS$29.6MSep 30, 2026
Segall Bryant & Hamill, LLC618KUS$28.5MSep 30, 2026
UBS592KUS$27.3MSep 30, 2026
BNP Paribas547KUS$25.2MSep 30, 2026
Principal540KUS$24.9MSep 30, 2026
Invesco525KUS$24.2MSep 30, 2026
Public Sector Pension Investment Board501KUS$21.8MSep 30, 2026
RBC501KUS$23.1MSep 30, 2026
Qube Research & Technologies Ltd487KUS$22.4MSep 30, 2026
Raymond James Financial Inc485KUS$22.3MSep 30, 2026
Nuveen477KUS$22MSep 30, 2026
ArrowMark Colorado Holdings LLC453KUS$20.8MSep 30, 2026
Jump Financial, LLC453KUS$20.8MSep 30, 2026
Sei Investments Co438KUS$20.1MSep 30, 2026
Man Group plc432KUS$19.9MSep 30, 2026
BNY430KUS$19.8MSep 30, 2026
Fred Alger Management, LLC404KUS$18.6MSep 30, 2026
Jupiter Asset Management LTD371KUS$17.1MSep 30, 2026
Silvercrest Asset Management Group LLC369KUS$17MSep 30, 2026
D. E. Shaw & Co., Inc.343KUS$15.8MSep 30, 2026
Los Angeles Capital Management LLC323KUS$14.9MSep 30, 2026

This page holds 50 of 373 holders. Open Shareholders

Funds

HolderSharesValueAs of
iShares Core S&P Small-Cap ETF4.81MUS$282MJun 30, 2026
Vanguard Total Stock Market Index Fund2.53MUS$149MJun 30, 2026
First Trust NYSE Arca Biotechnology Index Fund2.44MUS$143MJun 30, 2026
iShares Russell 2000 ETF2.08MUS$122MJun 30, 2026
Vanguard Small-Cap Index Fund1.83MUS$108MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.5MUS$87.9MJun 30, 2026
Select Health Care Portfolio1.28MUS$59.3MMay 31, 2026
Artisan Mid Cap Fund1.24MUS$72.6MJun 30, 2026
Vanguard Small-Cap Growth Index Fund1.05MUS$61.9MJun 30, 2026
ARK Innovation ETF1.03MUS$47.5MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Select Medical Technology and Devices Portfolio1MUS$46.3MMay 31, 2026
Vanguard Explorer Fund984KUS$45.6MJul 31, 2026
Fullerthaler Behavioral Small-Cap Growth978KUS$57.4MJun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund957KUS$56.2MJun 30, 2026
Vanguard Extended Market Index Fund915KUS$53.7MJun 30, 2026
Fidelity Small Cap Growth Fund893KUS$41.3MJul 31, 2026
Fidelity Small Cap Index Fund886KUS$41MJul 31, 2026
ARK Genomic Revolution ETF856KUS$39.7MJul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund805KUS$37.3MMay 31, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF731KUS$42.9MJun 30, 2026
iShares S&P Small-Cap 600 Growth ETF717KUS$42.1MJun 30, 2026
Fidelity Stock Selector Small Cap Fund664KUS$30.8MJul 31, 2026
Fidelity Advisor Health Care Fund600KUS$27.8MJul 31, 2026
iShares Russell 2000 Growth ETF582KUS$34.2MJun 30, 2026
iShares Biotechnology ETF551KUS$32.4MJun 30, 2026
Vanguard Tax-Managed Small-Cap Fund508KUS$29.9MJun 30, 2026
VIP Mid Cap Portfolio492KUS$28.9MJun 30, 2026
Oberweis Small-Cap Opportunities Fund487KUS$28.6MJun 30, 2026
Baron Discovery Fund469KUS$27.5MJun 30, 2026
Fidelity Small Cap Growth K6 Fund463KUS$21.5MJul 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF452KUS$26.6MJun 30, 2026
Strategic Advisers U.S. Total Stock Fund410KUS$19MMay 31, 2026
Fidelity Extended Market Index Fund409KUS$19MMay 31, 2026
U.S. Targeted Value Portfolio408KUS$18.9MJul 31, 2026
Vanguard Russell 2000 Index Fund403KUS$18.7MMay 31, 2026
William Blair Small Cap Growth Fund394KUS$23.1MJun 30, 2026
Fidelity Series Small Cap Opportunities Fund381KUS$17.7MJul 31, 2026
Schwab U.S. Small-Cap ETF381KUS$17.6MMay 31, 2026
Fidelity U.S. Equity Central Fund365KUS$21.4MJun 30, 2026
Dimensional U.S. Targeted Value ETF363KUS$16.8MJul 31, 2026
U.S. Small Cap Portfolio353KUS$16.4MJul 31, 2026
U.S. Micro Cap Portfolio287KUS$13.3MJul 31, 2026
Oberweis Micro-Cap Fund274KUS$16.1MJun 30, 2026
Vanguard S&P Small-Cap 600 Index Fund274KUS$12.7MMay 31, 2026
Artisan Small Cap Fund269KUS$15.8MJun 30, 2026
Dimensional U.S. Small Cap ETF266KUS$12.3MJul 31, 2026
AMG GW&K Small Cap Core Fund256KUS$15MJun 30, 2026
Vanguard Health Care Index Fund237KUS$11MMay 31, 2026
Driehaus Small Cap Growth Fund222KUS$13MJun 30, 2026
VIP Health Care Portfolio218KUS$12.8MJun 30, 2026

This page holds 50 of 360 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Eastham Karin
Director
Sale14,850USD 50.00US$743KOct 27, 2026
Holstein Jens
Director
Sale7,500USD 50.00US$375KOct 27, 2026
Bhanji Muna
Director
Sale1,864USD 43.70US$81,457Oct 19, 2026
Holstein Jens
Director
Sale7,500USD 47.00US$353KSep 24, 2026
Leite John
Officer: Global Chief Commercial Off
Sale4,015USD 40.00US$161KSep 21, 2026
Holstein Jens
Director
Sale5,000USD 40.95US$205KSep 14, 2026
Febbo Phillip G.
Officer: Chief Scientific & Med Officer
Sale10,405USD 42.89US$446KSep 4, 2026
Febbo Phillip G.
Officer: Chief Scientific & Med Officer
Sale2,705USD 43.66US$118KSep 4, 2026
Chambers Rebecca
Officer: Chief Financial Officer
Sale2,477USD 42.81US$106KSep 4, 2026
Chambers Rebecca
Officer: Chief Financial Officer
Sale1,175USD 43.71US$51,359Sep 4, 2026
All 25 trades
TradeTradeSharesPriceValueDate
McGuire Annie
Officer: EVP, General Counsel
Sale2,154USD 42.79US$92,170Sep 4, 2026
McGuire Annie
Officer: EVP, General Counsel
Sale1,100USD 43.67US$48,037Sep 4, 2026
Bhanji Muna
Director
Sale1,864USD 42.97US$80,096Sep 1, 2026
Eastham Karin
Director
Sale3,200USD 52.78US$169KJun 18, 2026
Eastham Karin
Director
Sale529USD 53.55US$28,328Jun 18, 2026
Stapley Marc
Director, Officer: Chief Executive Officer
Sale138,051USD 50.12US$6.92MJun 4, 2026
Chambers Rebecca
Officer: Chief Financial Officer
Sale1,600USD 49.28US$78,848Jun 4, 2026
Chambers Rebecca
Officer: Chief Financial Officer
Sale1,961USD 50.09US$98,226Jun 4, 2026
McGuire Annie
Officer: EVP, General Counsel
Sale1,400USD 49.31US$69,034Jun 4, 2026
McGuire Annie
Officer: EVP, General Counsel
Sale1,776USD 50.12US$89,013Jun 4, 2026
Leite John
Officer: Global Chief Commercial Off
Sale13,975USD 50.07US$700KJun 4, 2026
Wygant Jonathan
Officer: VP, Chief Accounting Officer
Sale24,000USD 45.40US$1.09MMay 22, 2026
Epstein Robert S
Director
Sale10,000USD 44.01US$440KMay 20, 2026
McGuire Annie
Officer: SVP, General Counsel
Sale5,102USD 38.05US$194KMay 6, 2026
McGuire Annie
Officer: SVP, General Counsel
Sale5,102USD 40.00US$204KMay 6, 2026

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.15.20%11.9MJul 31, 2025Schedule 13G
FMR LLC7.70%6.17MSep 30, 2026Schedule 13G
State Street Corp6.30%5.04MMar 31, 2026Schedule 13G
Vanguard Portfolio Management LLC5.67%4.51MMar 31, 2026Schedule 13G
Vanguard Capital Management LLC5.20%4.13MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Tina Susan Nova
Other companies: Aurinia Pharmaceuticals Inc (Director · Since at least May 15, 2025); Azenta, Inc. (Director · Since at least Feb 3, 2023); Exagen Inc. (Director · Since at least Sep 18, 2019); CapForce Inc. (Director · Apr 24, 2017 – Sep 2, 2019 · Past); NanoString Technologies Inc (Director · Apr 29, 2014 – Apr 29, 2014 · Past); DMK Pharmaceuticals Corporation (Director · Feb 10, 2011 – Oct 16, 2013 · Past); Genoptix Inc (President and CEO, Director · Oct 29, 2007 – Mar 7, 2011 · Past); Cypress Bioscience Inc (Director · Apr 26, 2007 – Jan 4, 2010 · Past); Arena Pharmaceuticals Inc (Director · Jul 28, 2006 – Mar 11, 2022 · Past)
President, CLIA U.S. · Nov 12, 2015 – Mar 3, 2022 · Past
John Bishop
Other companies: Ardelyx, Inc. (Chief Technical and Quality Officer · Since at least Aug 1, 2025); Lyra Therapeutics, Inc. (Chief Technology Officer · Feb 27, 2023 – Jan 30, 2024 · Past); Forma Therapeutics Holdings Inc (SVP, Chief Technology Officer · Jun 14, 2021 – Oct 14, 2022 · Past); Cepheid (Chairman of the Board and CEO, Director · Feb 26, 2009 – Nov 4, 2016 · Past); Conceptus Inc (Director · Feb 25, 2009 – Jun 5, 2013 · Past); Momenta Pharmaceuticals Inc (Senior VP, Pharmaceutical Scie · Feb 17, 2006 – May 19, 2016 · Past)
Director · Dec 1, 2014 – Jul 17, 2023 · Past
Jesse I Treu
Other companies: CoLucid Pharmaceuticals Inc (Director · May 5, 2015 – May 11, 2015 · Past); Aldeyra Therapeutics, Inc. (Director · May 1, 2014 – Jun 9, 2020 · Past); Tandem Diabetes Care, Inc. (Director · Nov 13, 2013 – Nov 15, 2016 · Past); Tobira Therapeutics Inc (Director · Aug 21, 2013 – Jan 1, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Mar 3, 2010 – Jun 9, 2010 · Past)
Director · Oct 29, 2013 – Feb 28, 2019 · Past
Brook H Byers
Other companies: CareDx, Inc. (Director · Jul 16, 2014 – Apr 1, 2016 · Past); Foundation Medicine Inc (Director · Sep 24, 2013 – Apr 7, 2015 · Past); Pacific Biosciences of California, Inc. (Director · Oct 26, 2010 – May 17, 2016 · Past); Genomic Health Inc (Director · May 25, 2006 – Apr 1, 2011 · Past)
Director · Oct 29, 2013 – May 20, 2014 · Past
Evan Jones
Other companies: CapForce Inc. (Director · May 4, 2015 – May 17, 2021 · Past); Foundation Medicine Inc (Director · Sep 24, 2013 – Jul 31, 2018 · Past); CAS Medical Systems Inc (Director · Jun 20, 2012 – Jun 24, 2013 · Past); Standard BioTools Inc. (Director · Dec 12, 2011 – Jul 31, 2017 · Past)
Board Member · Since at least Oct 29, 2013
Karin Eastham
Other companies: Personalis, Inc. (Chair · Since at least Sep 9, 2019); Nektar Therapeutics (Director · Sep 27, 2018 – Sep 16, 2022 · Past); Geron Corporation (Director · May 17, 2016 – Jan 13, 2023 · Past); Illumina, Inc. (Director · May 17, 2016 – May 28, 2019 · Past)
Board Member · Since at least Jun 20, 2016
Kevin Gordon
Other companies: Progyny, Inc. (Director · Since at least Oct 24, 2019); IQVIA Holdings, Inc. (EVP and COO · May 8, 2013 – Jun 9, 2016 · Past); Teleflex Incorporated (Exec. Vice Pres. & CFO · Dec 25, 2005 – Dec 31, 2009 · Past)
Director · Dec 12, 2016 – Jun 8, 2022 · Past
Muna Bhanji
Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Apr 28, 2022); Ardelyx, Inc. (Director · Since at least Mar 11, 2021); Cytokinetics, Incorporated (Director · Since at least Feb 17, 2021)
Director · Since at least Mar 19, 2021
Rebecca Chambers
Other companies: Alamar Biosciences, Inc. (Director · Since at least Apr 16, 2026); Inari Medical Inc (Director · Jun 21, 2021 – Feb 19, 2025 · Past); Outset Medical, Inc. (Chief Financial Officer · Sep 14, 2020 – Jun 24, 2021 · Past)
Chief Financial Officer · Since at least Jul 19, 2021
Brent Shafer
Other companies: Tactile Systems Technology, Inc. (Director · Since at least Nov 5, 2026); Baxter International Inc. (Chair of the Board, Former Chair · Since at least May 4, 2026)
Board Member · Since at least Nov 6, 2024
All 28 people
PersonSeat
David Brent Shafer
Other companies: Tactile Systems Technology, Inc. (Director · Since at least May 6, 2026); Baxter International Inc. (Director · Since at least May 5, 2026)
Director · Since at least Jun 11, 2026
Keith Kennedy
Other companies: CareDx, Inc. (Chief Financial Officer and Chief Operating Officer · Since at least Sep 12, 2024); MCG Capital Corp (President and CEO, Director · Aug 14, 2015 – Aug 18, 2015 · Past)
COO / CFO · Dec 6, 2016 – Mar 2, 2021 · Past
Beverly Jane Alley
Other companies: MCG Capital Corp (CFO · Mar 15, 2012 – Aug 18, 2015 · Past)
VP, Corporate Controller · Apr 1, 2021 – May 17, 2021 · Past
Bonnie H Anderson
Other companies: Bruker Corporation (Director · Since at least Jan 5, 2023)
Director · May 1, 2022 – Jun 2, 2023 · Past
Christopher Hall
Other companies: Personalis, Inc. (Director · Since at least Dec 31, 2022)
President and COO · Jul 22, 2015 – Jun 3, 2019 · Past
Kevin Haas
Other companies: Myriad Genetics, Inc. (Chief Technology Officer · Since at least Feb 2, 2026)
Chief Development and Technology Officer · Since at least Mar 16, 2026
Marc A. Stapley
Other companies: Glaukos Corporation (Director · Since at least May 30, 2019)
Chief Executive Officer, Director · Since at least Jun 1, 2021
Phillip G Febbo
Other companies: Illumina, Inc. (SVP Chief Medical Officer · Apr 5, 2022 – Mar 1, 2023 · Past)
Chief Scientific & Med Officer · Since at least Oct 2, 2023
Robert S. Epstein
Other companies: Fate Therapeutics, Inc. (Board Member · Since at least May 5, 2026)
Director · Since at least May 20, 2026
Annie McGuireEVP, General Counsel · Since at least Feb 28, 2022
Eliav BarrBoard Member · Since at least Aug 9, 2022
Giulia C KennedyChief Scientific & Med Officer · Feb 21, 2019 – Dec 6, 2022 · Past
Jens HolsteinBoard Member · Since at least Jun 18, 2025
John LeiteGlobal Chief Commercial Off · Since at least Sep 1, 2023
Jonathan WygantVP, Chief Accounting Officer · Since at least Aug 5, 2022
Marc StapelyUntil Sep 4, 2026 · Past
Thomas F MillerDirector · Since at least Sep 3, 2024
Tom MillerDirector · Since at least Nov 6, 2024

Open People

Log in to ask 6ix AI your own questions about Veracyte, Inc.